Integra LifeSciences Ownership
| IART Stock | USD 21.82 0.36 1.62% |
Integra |
Integra Stock Ownership Analysis
About 14.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.11. Some equities with similar Price to Book (P/B) outperform the market in the long run. Integra LifeSciences has Price/Earnings To Growth (PEG) ratio of 1.12. The entity recorded a loss per share of 0.09. The firm had not issued any dividends in recent years. Integra LifeSciences had 2:1 split on the 4th of January 2017. Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. Integra Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 3800 people. To learn more about Integra LifeSciences Holdings call Jan Witte at 609 275 0500 or check out https://www.integralife.com.Integra LifeSciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Integra LifeSciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Integra LifeSciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Integra LifeSciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Integra LifeSciences Outstanding Bonds
Integra LifeSciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Integra LifeSciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Integra bonds can be classified according to their maturity, which is the date when Integra LifeSciences Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US457985AM13 Corp BondUS457985AM13 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.